FDA probing whether Intercept Pharma drug is tied to risk of liver injury

FDA probing whether Intercept Pharma drug is tied to risk of liver injury

STAT Plus: FDA investigating whether Intercept Pharma drug is tied to potential liver injury risk

By ADAM FEUERSTEIN

HYACINTH EMPINADO/STAT

The company disclosed the inquiry in several new sentences added deep in an existing risk-statement section of a quarterly report.

READ MORE